

Supplementary Information

The Impact Of Afatinib On Survival In Advanced Non-Small Cell Lung Cancer: A Meta-Analysis Of Randomized Controlled Trials

Chi Wang,¹ Yun Li¹, Li Ke², Lejie Cao³, Pingsheng Fan⁴, Zhiwei Wu¹, Quan Wu^{1*}

1 Central Laboratory of Medical Research Centre, Anhui Provincial Hospital, Anhui Medical University, Hefei, 230001, China

2 Department of Thoracic Surgery, Anhui Provincial Hospital, Anhui Medical University, Hefei, 230001, China

3 Department of Respiration, Anhui Provincial Hospital, Anhui Medical University, Hefei, 230001, China

4 Department of Oncology, Anhui Provincial Hospital, Anhui Medical University, Hefei, 230001, China

Email addresses:

Chi Wang: iswangch@126.com

Yun Li: 18326660963@163.com

Li Ke: Keli_kl@163.com

Lejie Cao: sycaolejie@163.com

Pingsheng Fan: fanpingsheng@csc.org.cn

Zhiwei Wu: 35wu@sina.com


Quan Wu: powerwoo01@ahmu.edu.cn

*Corresponding author:

Dr. Quan Wu

Address for correspondence: Central Laboratory of Medical Research Centre


17 Lujian Road, Luyang District, Hefei, China




Supplemental Figure 1 Risk of bias graph

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Machiels 2015	+	?	-	-	+	+	+
Miller 2012	+	?	+	+	+	+	+
Park 2016	+	?	-	-	+	+	+
Schuler 2016	?	?	+	+	+	+	+
Sequist 2013	?	?	-	-	+	+	+
Soria 2015	+	?	-	-	+	+	+
Wu 2014	+	+	-	-	+	+	+


Supplemental Figure 2 Risk of bias summary




Supplemental Figure3 The funnel plot of included studies



Supplemental Figure 4 Forest plots of relative risk (RR) for Diarrhea comparing afatinib-based regimens to the control arm



Supplemental Figure 5 Forest plots of relative risk (RR) for Rash comparing afatinib-based regimens to the control arm



Supplemental Figure 6 Forest plots of relative risk (RR) for Stomatitis comparing afatinib-based regimens to the control arm